Tvardi Therapeutics (NASDAQ:TVRD) Stock Moved Up to “Sell” by Wall Street Zen

Wall Street Zen upgraded shares of Tvardi Therapeutics (NASDAQ:TVRD) from a strong sell rating to a sell rating in a research report report published on Sunday,Wall Street Zen reports.

A number of other equities analysts also recently commented on TVRD. Lucid Cap Mkts upgraded shares of Tvardi Therapeutics to a “strong-buy” rating in a research note on Tuesday, September 8th. Raymond James Financial upgraded Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price target on the stock in a research note on Wednesday, July 8th. UBS Group raised Tvardi Therapeutics to an “outperform” rating and set a $10.00 price target for the company in a report on Wednesday, July 8th. HC Wainwright assumed coverage on Tvardi Therapeutics in a research report on Monday, June 8th. They set a “buy” rating and a $9.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Tvardi Therapeutics Price Performance

Shares of Tvardi Therapeutics stock opened at $1.15 on Friday. Tvardi Therapeutics has a 52-week low of $0.93 and a 52-week high of $43.65. The company has a market capitalization of $15.34 million, a P/E ratio of -0.41 and a beta of 0.38. The company has a 50 day moving average of $1.77 and a 200 day moving average of $2.64.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). As a group, research analysts anticipate that Tvardi Therapeutics will post -2.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of TVRD. Susquehanna International Group LLP purchased a new stake in Tvardi Therapeutics in the second quarter valued at $63,000. BlackRock Inc. acquired a new position in Tvardi Therapeutics in the second quarter valued at $181,000. Finally, GSA Capital Partners LLP purchased a new position in shares of Tvardi Therapeutics during the second quarter worth about $34,000. Institutional investors and hedge funds own 44.66% of the company’s stock.

About Tvardi Therapeutics

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for cancer and other serious diseases driven by abnormal STAT3 signaling. The company’s approach is designed to address tumor growth, immune suppression and resistance to existing therapies by selectively targeting STAT3, a protein involved in cancer progression.

Tvardi’s lead product candidate is TTI-101, an orally administered small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors.